Samsung Bioepis Co., Ltd.
http://www.samsungbioepis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samsung Bioepis Co., Ltd.
Bluebird’s Eli-Cel Gene Therapy Among Myriad New Drugs Seeking EU Approval
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Samsung Bioepis First To File EU Lucentis Rival
Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.
Samsung Bioepis Receives EU Bevacizumab Approval
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA
- MORE